HRAS and neoplasm: Eleven of the shortlisted genes were downregulated in cisplatin-resistant tumours, low expression was found to be unfavourable in neuroblastoma, one gene, HRAS, was upregulated in cisplatin-resistant tumours, and high expression was found to be unfavourable in neuroblastoma.